Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

• Status: Active, not recruiting
• Trial end date: 2025-02-10

Summary

This phase I/II trial studies the side effects and best dose of brentuximab vedotin that can be combined with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with an ifosfamide, carboplatin, and etoposide chemotherapy regimen may kill more cancer cells.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: University of Washington
• Collaborators: National Cancer Institute (NCI); Seagen Inc.
• Treatments: Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Brentuximab Vedotin; Carboplatin; Etoposide; Etoposide phosphate; Ifosfamide; Immunoconjugates; Immunoglobulins; Isophosphamide mustard; Podophyllotoxin